Financial Snapshot

Revenue
$0.00
TTM
Gross Margin
Net Earnings
-$2.608M
TTM
Current Assets
Current Liabilities
Current Ratio
Total Assets
Total Liabilities
Book Value
Cash
P/E
-0.8413
Nov 29, 2024 EST
Free Cash Flow
-$2.708M
TTM

Revenues

Revenues

Loading...

Revenue YoY Change

Loading...

Revenues

Concept 2023 2022 2021 2020 2019 2018 2017 2016 2015
Revenue $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00
YoY Change

Expenses

Cost Of Revenues

Loading...

Gross Profit

Loading...

Gross Profit Margin

Loading...

Gross Profit

Concept 2023 2022 2021 2020 2019 2018 2017 2016 2015
Revenue $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00
Cost Of Revenue
Gross Profit
Gross Profit Margin

Selling, General & Admin Expense

Loading...

Research & Development

Loading...

Depreciation, Depletion & Amortization

Loading...

SGA Expense to Gross Profit Ratio

Loading...

R&D To Gross Profit Ratio

Loading...

DDA To Gross Profit Ratio

Loading...

Operating Expenses Total

Loading...

Operating Profits/Loss

Loading...

Operational Expenses

Concept 2023 2022 2021 2020 2019 2018 2017 2016 2015
Selling, General & Admin $4.145M $3.727M $3.254M $5.986M $1.306M $838.1K $1.081M $2.736M $320.3K
YoY Change 11.23% 14.52% -45.63% 358.48% 55.77% -22.46% -60.49% 754.17%
% of Gross Profit
Research & Development $1.046M $2.293M $4.797M $2.692M $581.4K $69.47K $243.5K $150.6K $105.8K
YoY Change -54.37% -52.19% 78.23% 362.95% 736.89% -71.47% 61.69% 42.35%
% of Gross Profit
Depreciation & Amortization $50.40K $34.94K $0.00 $27.00K $40.95K $127.5K $47.96K $0.00
YoY Change 44.25% -100.0% -34.07% -67.89% 165.93%
% of Gross Profit
Operating Expenses $5.242M $6.020M $8.051M $8.677M $1.914M $948.6K $1.452M $2.935M $426.1K
YoY Change -12.92% -25.23% -7.21% 353.37% 101.77% -34.67% -50.52% 588.67%
Operating Profit
YoY Change

Interest Expenses

Loading...

Interest Expenses To Operating Income %

Loading...

Other Expense/Income

Loading...

Interest & Other Expense/Income

Concept 2023 2022 2021 2020 2019 2018 2017 2016 2015
Interest Expense $2.100K $2.080K $317.0K $35.08K $6.720K $10.96K $7.250K $7.170K $340.00
YoY Change 0.96% -99.34% 803.76% 422.02% -38.69% 51.17% 1.12% 2008.82%
% of Operating Profit
Other Income/Expense, Net $0.00 $14.68K
YoY Change -100.0%

Income/Loss

Pretax Income

Loading...

Income Tax

Loading...

Net Profits/Loss

Loading...

Pretax Income YoY Change

Loading...

Income Tax Rate

Loading...

Net Profits/Loss YoY Change

Loading...

Basic EPS

Loading...

Net Income To Revenue Ratio

Loading...

Pretax & Net Income

Concept 2023 2022 2021 2020 2019 2018 2017 2016 2015
Pretax Income -$6.781M -$6.054M -$7.734M -$8.538M -$1.896M -$937.6K -$1.891M -$6.877M -$425.8K
YoY Change 12.01% -21.72% -9.42% 350.43% 102.17% -50.41% -72.51% 1515.14%
Income Tax
% Of Pretax Income
Net Earnings -$6.781M -$6.054M -$7.734M -$8.538M -$1.896M -$937.6K -$1.891M -$6.877M -$425.8K
YoY Change 12.01% -21.72% -9.42% 350.43% 102.17% -50.41% -72.51% 1515.14%
Net Earnings / Revenue
Basic Earnings Per Share
Diluted Earnings Per Share -$0.45 -$3.483M -$4.965M -$9.694M -$4.244M -$6.658M -$7.366M -$39.00M -$21.44K

Assets & Liabilities

Cash & Short-Term Investments

Loading...

Cash & Equivalents

Loading...

Cash To Operating Expenses Ratio

Loading...

Inventory

Loading...

Receivables

Loading...

Total Short-Term Assets

Loading...

Property, Plant And Equipment

Loading...

Long-Term Investments

Loading...

Total Long-Term Assets

Loading...

Total Assets

Loading...

Net Income To Total Assets Percentage

Loading...

Accounts Payable

Loading...

Short-Term Debt

Loading...

Long Term Debt Due

Loading...

Total Short-Term Liabilities

Loading...

Long-Term Debt

Loading...

Other Long-Term Liabilities

Loading...

Total Long-Term Liabilities

Loading...

Total Liabilities

Loading...

Short-Term To Long-Term Debt Ratio

Loading...

Short-Term Assets To Debt Ratio

Loading...

Long-Term Debt To Net Income Ratio

Loading...

Assets & Liabilities

Concept 2023 2022 2021 2020 2019 2018 2017 2016 2015
Cash & Short-Term Investments $125.1K $1.409M $2.411M $6.121M $207.8K $1.251M $1.393M $1.598M $1.400M
YoY Change -91.12% -41.58% -60.61% 2845.68% -83.39% -10.16% -12.84% 14.14%
Cash & Equivalents $125.1K $1.409M $2.411M $6.121M $207.8K $1.251M $1.393M $1.598M $1.400M
Short-Term Investments
Other Short-Term Assets $118.7K $753.1K $203.2K $387.4K $26.26K $32.37K $68.11K $79.30K $0.00
YoY Change -84.24% 270.56% -47.54% 1375.06% -18.88% -52.47% -14.11%
Inventory
Prepaid Expenses
Receivables $2.295M $1.229M $44.79K $11.27K $9.230K $34.40K $0.00
Other Receivables $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00
Total Short-Term Assets $339.8K $2.827M $4.909M $7.738M $278.9K $1.295M $1.470M $1.711M $1.400M
YoY Change -87.98% -42.41% -36.56% 2674.95% -78.46% -11.92% -14.12% 22.26%
Property, Plant & Equipment $0.00 $53.80K $67.96K $27.84K $0.00
YoY Change -100.0% -20.84% 144.11%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $57.50K $57.50K $57.50K $57.50K $58.87K $1.370K $1.370K $1.370K $1.370K
YoY Change 0.0% 0.0% 0.0% -2.33% 4197.08% 0.0% 0.0% 0.0%
Total Long-Term Assets $3.854M $5.314M $5.228M $5.086M $5.059M $128.2K $166.7K $561.7K $1.370K
YoY Change -27.47% 1.63% 2.8% 0.52% 3846.06% -23.09% -70.32% 40899.27%
Total Assets $4.194M $8.141M $10.14M $12.82M $5.338M $1.423M $1.637M $2.273M $1.401M
YoY Change
Accounts Payable $2.720M $2.516M $1.022M $607.1K $365.5K $57.03K $47.75K $150.4K $173.4K
YoY Change 8.09% 146.12% 68.41% 66.11% 540.82% 19.43% -68.25% -13.26%
Accrued Expenses
YoY Change
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $2.720M $2.516M $1.022M $607.1K $365.5K $57.03K $47.75K $150.4K $173.4K
YoY Change 8.09% 146.12% 68.41% 66.11% 540.82% 19.43% -68.25% -13.26%
Long-Term Debt $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00
YoY Change
Other Long-Term Liabilities
YoY Change
Total Long-Term Liabilities $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00
YoY Change
Total Liabilities $2.720M $2.516M $1.022M $607.1K $365.5K $57.03K $47.75K $150.4K $173.4K
YoY Change 8.09% 146.12% 68.41% 66.11% 540.82% 19.43% -68.25% -13.26%

Ownership

Basic Shares Outstanding

Loading...

Diluted Shares Outstanding

Loading...

Preferred Stock

Loading...

Treasury Stock Shares

Loading...

Stock Issuance & Repurchase

Loading...

Ownership Data

Concept 2023 2022 2021 2020 2019 2018 2017 2016 2015
Basic Shares Outstanding
Diluted Shares Outstanding
Preferred Stock
Treasury Stock Shares

Return On Shareholders' Equity

Loading...

Book Value

Loading...

Free Cash Flow

Loading...

Free Cash Flow YoY

Loading...

Free Cash Flow Margin

Loading...

Dividends

Dividends

Loading...

Stock Price

Loading...
Market Cap: $2.1941 Million

About Algernon Pharmaceuticals Inc.

Algernon Pharmaceuticals, Inc. is a drug re-purposing company that investigates safe, already approved drugs, including naturally occurring compounds, for new disease applications, moving them into new human trials, developing new formulations and seeking new regulatory approvals in global markets. The company is headquartered in Vancouver, British Columbia. The company went IPO on 2016-02-01. The firm is focused on developing repurposed therapeutic drugs in the areas of non-alcoholic steatohepatitis (NASH), a type of liver disease, chronic kidney disease (CKD), inflammatory bowel disease (IBD), idiopathic pulmonary fibrosis (IPF) and chronic cough as well as advancing a stroke program using N, N-Dimethyltryptamine (DMT). The firm operates through two segments, which includes the development of repurposed therapeutic drugs in Canada and the facilitation of the Company’s lead drug candidates into off-label phase II clinical trials (humans) in Australia. The firm's pipeline includes NP-251 (Repirinast) and AP-188 (DMT). The Company, through its subsidiary, Algernon NeuroScience Inc., is developing AP-188 (DMT) as a potential treatment for stroke and traumatic brain injury (TBI) recovery. Its NP-251 is being developed as a potential treatment for kidney inflammation and fibrosis.

Industry: Pharmaceutical Preparations Peers: